These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37537545)

  • 1. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group.
    Everest L; Chen BE; Hay AE; Cheung MC; Chan KKW
    BMC Med Res Methodol; 2023 Aug; 23(1):179. PubMed ID: 37537545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter?
    Hollingworth W; McKell-Redwood D; Hampson L; Metcalfe C
    Clin Trials; 2013 Feb; 10(1):43-53. PubMed ID: 23231969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials.
    Cheung MC; Chan KK; Golden S; Hay A; Pater J; Prica A; Chen BE; Leighl N; Mittmann N
    Clin Trials; 2021 Aug; 18(4):500-504. PubMed ID: 33866856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation.
    Riley P; Glenny AM; Worthington HV; Jacobsen E; Robertson C; Durham J; Davies S; Petersen H; Boyers D
    Health Technol Assess; 2020 Feb; 24(7):1-224. PubMed ID: 32065109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data.
    Willan AR
    Control Clin Trials; 2001 Jun; 22(3):228-37. PubMed ID: 11384787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Power and sample size calculations for stochastic cost-effectiveness analysis.
    Briggs AH; Gray AM
    Med Decis Making; 1998; 18(2 Suppl):S81-92. PubMed ID: 9566469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.
    Li L; Uyei J; Nucifora KA; Kessler J; Stevens ER; Bryant K; Braithwaite RS
    BMC Health Serv Res; 2018 Jul; 18(1):590. PubMed ID: 30064428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
    Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A
    Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Power and sample size for cost-effectiveness analysis: fFN neonatal screening.
    Boyd KA; Briggs AH; Fenwick E; Norrie J; Stock S
    Contemp Clin Trials; 2011 Nov; 32(6):893-901. PubMed ID: 21782976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials.
    Flight L; Julious S; Brennan A; Todd S
    Med Decis Making; 2022 May; 42(4):461-473. PubMed ID: 34859693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
    Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
    J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
    Sarker SJ; Whitehead A; Khan I
    Comput Methods Programs Biomed; 2013 Jun; 110(3):471-89. PubMed ID: 23399102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An opportunity cost approach to sample size calculation in cost-effectiveness analysis.
    Gafni A; Walter SD; Birch S; Sendi P
    Health Econ; 2008 Jan; 17(1):99-107. PubMed ID: 17497751
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.